



## Biomarkers and Drug Candidates for the Treatment of Neuroinflammation

Guest Editors:

**Dr. Gabriella Juhasz**

Department of  
Pharmacodynamics, Faculty of  
Pharmaceutical Sciences,  
Semmelweis University,  
Budapest, Hungary

**Dr. Xenia Gonda**

1. Department of Psychiatry and Psychotherapy, Semmelweis University, 1085 Budapest, Hungary
2. Department of Clinical Psychology, Semmelweis University, 1092 Budapest, Hungary
3. NAP3.0 Neuropsychopharmacology Research Group, Hungarian Academy of Sciences and Semmelweis University, 1089 Budapest, Hungary

Deadline for manuscript  
submissions:

**closed (31 October 2022)**



[mdpi.com/si/121927](https://mdpi.com/si/121927)

### Message from the Guest Editors

Dear Colleagues,

Recent discoveries suggest that beside the traditional neuroinflammatory disorders, such as multiple sclerosis, neuroinflammation has an important contribution to the development and outcome of several other neurologic conditions and psychiatric disorders. However, the interplay between the immune system and the central nervous system (CNS) is very complex, allowing both adaptive and pathological immunological processes, and thus identifying therapeutic targets are challenging and conditional on better understanding of neuroinflammatory disease mechanisms.

.....

This Special Issue embracing research focusing on neuroinflammation and related biomarkers in order to identify drug candidates in the service of better understanding and treating neuropsychiatric disorders and aims to provide readers with the most recent advances in this field. Authors are invited to submit relevant original articles, reviews or short communications for inclusion.

Dr. Gabriella Juhasz

Dr. Xenia Gonda

*Guest Editors*



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research

Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA

2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)